{
  "original_text": "拓普基因, 检测项目, 受检者：林列蓉, TopGene, www.topgene.cn, 洛氏伐Small-实体瘤基因检测, 报告编号：LSFS-202304-012, Atezolizumab and Cobimetinib or Id, 6485, asanutlin in Participants With Stage I, 美国, 11/28, 是, 进行中, NA, V or Unresectable Recurrent Estroge, 尚未招募, n Receptor Positive Breast Cancer, A Phase 1b/2 Study of Serabelisib in, 进行中, NCT04073680, Combination With Canagliflozin in P, 美国, 是, NA, 尚未招募, atients With Advanced Solid Tumors, A Study of Fluzoparib Given in Comb, 进行中, NCT03075462, ination With Apatinib in Ovarian or B, 北京肿瘤医院, 否, NA, 尚未招募, reast Cancer Patients, The UK Plasma Based Molecular Prof, iling of Advanced Breast Cancer to In, NCT03182634, 英国, 否, 招募中, NA, form Therapeutic CHoices(plasmaM, ATCH)Trial(plasmaMATCH), Molecular Mechanisms of Resistance, NCT03184090, and Sensitivity to Palbociclib Re-chal, 意大利、西班牙, 否, 招募中, NA, lenge in ER+ mBC(BioPER), Phase 1/2 Study of SAR439859 Sing, le Agent and in Combination With Pa, 美国等全球多家, NCT03284957, lbociclib in Postmenopausal Women, 否, 招募中, NA, 机构, With Estrogen Receptor Positive Adv, anced Breast Cancer, Preoperative Palbociclib in Patients, NCT03535506, With DCIS of the Breast That Are Can, 美国, 否, 招募中, NA, didates for Surgery(WI223281), Investigation of Anti-tumour Effect a, nd Tolerability of the PARP Inhibitor, NCT03562832, 2X-121 in Patients With Metastatic Br, 丹麦, 否, 招募中, NA, east Cancer Selected by the 2X-121, DRP, 军事医学科学院, CTR20131895, 融合蛋白临床研究, 附属医院国家药, 否, 招募中, NA, 物临床试验机构, 中国医学科学院, Palbociclib联合来曲唑治疗亚洲女性绝, 肿瘤研究所肿瘤, CTR20140573, 否, 招募中, NA, 经后晚期乳腺癌, 医院等全国及全, 球五十多家医院, 复旦大学附属肿, 在局部复发或转移性乳腺癌绝经后女性, 健康随我, CTR20160365, 瘤医院等全国多, 否, 招募中, 中LY2835219的3期研究, 家机构, 行App, 针对晚期恶性实体肿瘤的LXI-150291, 中国医学科学院, CTR20170273, 否, 招募中, NA, 期研究, 肿瘤医院, 长春中医药大学, 评价我们的甲苯磺酸拉帕替尼片与泰立, CTR20170451, 附属医院药物临, 否, 招募中, NA, 沙是否生物等效, 床试验机构, CTR20170699, 评价TK006在乳腺癌骨转移患者中的, 南京医科大学第, 期临床研究, 一附属医院, 否, 招募中, NA, 第9页, 医学检验实验室地址：广州国际生物岛螺旋三路8号第八层802单元, 电话：4006-268-862, 邮编：510005",
  "cleaned_text": null
}